| Literature DB >> 12745147 |
Abstract
Schistosomiasis continues to be a significant health problem, especially in Africa. While the recent World Health Assembly resolution to apply mass drug treatment of school age children in endemic areas is a very promising development, a preferable long-term solution would be provided by a protective vaccine. Encouragingly, one vaccine, Bilhvax, is in phase II trials. However, there is a danger that momentum towards the goal of developing a vaccine against schistosomiasis is dissipating. This article reviews the current situation in this important area of schistosomiasis research.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12745147 DOI: 10.1016/s0001-706x(03)00062-7
Source DB: PubMed Journal: Acta Trop ISSN: 0001-706X Impact factor: 3.112